Myasthenia gravis

2023 - 1 - 25

Post cover
Image courtesy of "PRNewswire"

Myasthenia Gravis Foundation of America (MGFA) Re-launches the ... (PRNewswire)

The MGFA registry enables MG patients to safely, securely, and confidentially contribute their health and symptom data to help researchers design and drive ...

Research leveraging the registry will be shared with participants, so that they stay actively involved throughout the process and see how their contribution of data benefits the community. The MGFA registry enables MG patients to safely, securely, and confidentially contribute their health and symptom data to help researchers design and drive research studies and clinical trials for making MG discoveries and finding better treatments to improve MG patient outcomes. "Patients from around the world require data privacy, and now they can safely and securely share their data to help research sponsors make MG discoveries that could lead to better outcomes and treatments. The MGFA registry is a powerful, real-world data source that will enable research and clinical trials with access to recruitment and direct patient insights. "We see a future where patients are empowered to carry their own end-to-end health care information to obtain more effective treatments, better manage a disease, be healthier, or actively equip their circle of care to assist them," said Gabriele Brambilla, chief executive officer of Alira Health. Alira Health has provided new, more efficient methods for patients to submit their data via a mobile phone application called Health Storylines™, as well as analytical support to unlock insights from the registry.

Post cover
Image courtesy of "Yahoo Finance"

Myasthenia Gravis Foundation of America (MGFA) Re-launches the ... (Yahoo Finance)

Patients living with myasthenia gravis (MG) provide their health and symptom experience data in a safe, secure registry to drive new research and ...

Myasthenia Gravis Foundation of America (MGFA) re-launches the ... (EurekAlert)

Patients living with myasthenia gravis (MG) provide their health and symptom experience data in a safe, secure registry to drive new research and ...

Research leveraging the registry will be shared with participants, so that they stay actively involved throughout the process and see how their contribution of data benefits the community. The MGFA registry enables MG patients to safely, securely, and confidentially contribute their health and symptom data to help researchers design and drive research studies and clinical trials for making MG discoveries and finding better treatments to improve MG patient outcomes. The MGFA registry is a powerful, real-world data source that will enable research and clinical trials with access to recruitment and direct patient insights. “Patients from around the world require data privacy, and now they can safely and securely share their data to help research sponsors make MG discoveries that could lead to better outcomes and treatments. We are honored to partner with them to help improve the lives of patients with myasthenia gravis.” The re-launch of the registry capitalizes on technological advances and better understanding of MG.

Post cover
Image courtesy of "Myasthenia Gravis News"

Enrollment Begins for MuSK Myasthenia Gravis Clinical Trial |... (Myasthenia Gravis News)

Researchers have developed a cell-based therapy to kill off disease-driving immune cells in MuSK-associated myasthenia gravis.

The goal of the Phase 1 trial is to evaluate the therapy’s safety and tolerability across two phases. When infused back into a patient’s bloodstream, the therapy is expected to specifically target and kill these autoreactive B-cells. Food and Drug Administration (FDA) [cleared in March 2022](https://myastheniagravisnews.com/news/mg-based-therapy-clinical-trial-planned-fda/). MuSK-CAART was developed in Payne’s laboratory and later licensed to Cabaletta for clinical development. In the Cabaletta-sponsored study, researchers tested the CAAR T-cell therapy in cell cultures and mouse models of MG. [myasthenia gravis](https://myastheniagravisnews.com/what-is-myasthenia-gravis/) (MG) patients with anti-MuSK antibodies, eliminated disease-driving B-cells in a mouse model of the disease, a study showed.

Explore the last week